Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05961839 · ClinicalTrials.gov registry record · Phase 1
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Phase 1 study, sponsored by Schrödinger.
- Terminated
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT05961839: Clinical Trial Phase 1 study, sponsored by Schrödinger.
NCT05961839 is a Phase 1 study that was terminated before completion, run by Schrödinger. The registered enrollment target is 66 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05961839, a Phase 1 study, was terminated before completion, sponsored by Schrödinger.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
Interventions
- DRUG SGR-2921
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-09-27 |
| Est. Completion | 2025-09-09 |
| Phase | Phase 1 |
Why NCT05961839 stopped before completion
NCT05961839 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 1 intervention - of which SGR-2921 is the first listed.
NCT05961839 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05961839 about?
NCT05961839 is a clinical study titled "Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome". The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921.
What is the current status of trial NCT05961839?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2023-09-27. Estimated completion is 2025-09-09.
What interventions are being tested in trial NCT05961839?
The interventions under investigation include: SGR-2921 (DRUG).
Who is sponsoring clinical trial NCT05961839?
This trial is sponsored by Schrödinger, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05961839's enrollment target sits among peer trials
66 786th of 2000 higher than 1,203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI